Chicago Clinical Research Institute Expands into Phase I Trials with 10-Year Lease at Rosalind Franklin University
Event summary
- Chicago Clinical Research Institute (CCRII) signs 10-year lease for Phase I/II clinical trial site at Rosalind Franklin University's Innovation and Research Park.
- New 3,000-square-foot facility addresses Illinois shortage of Phase I clinical trial capacity.
- CCRII brings 250+ clinical trials experience across 12 therapeutic areas to the North Chicago location.
- Strategic alignment with RFU's medical, pharmacy, and nursing schools for talent pipeline.
The big picture
This expansion addresses a critical gap in Illinois' drug development ecosystem, potentially reducing out-of-state trial migration. The partnership leverages RFU's academic resources while positioning CCRII to capture more of the state's estimated 50 annual Phase I trials. The move comes as states increasingly compete to attract and retain clinical research infrastructure.
What we're watching
- Capacity Utilization
- Whether CCRII can fill the new facility with Illinois' estimated 50 annual Phase I trials.
- Talent Pipeline
- How RFU's academic programs will support CCRII's staffing needs for expanded operations.
- Regional Competition
- The pace at which other states respond to Illinois' improved Phase I trial infrastructure.
Related topics